By Christine A. Wu, Research Analyst, LSN
Venture philanthropy has been a vital source of capital for early stage life science companies over the years. Philanthropic organizations provide more than just financing; a foundation with a niche indication focus may supply a network of experts, patients, and resources in the field. These organizations have an underlying mission to improve specific patient outcomes, going as far as using their financial returns toward further initiatives and investments to achieve their mission. Due to these organizations’ unique missions, LSN has uncovered a number of investment trends and accumulated advice in how to approach venture philanthropy investors.
LSN is pleased to announce a panel of five expert representatives in the venture philanthropy space for the RESI San Francisco Conference on January 12th. Moderated by Chris de Souza, Director of Broadview Ventures, the panel will be joined by:
- Lindy Fishburne, Executive Director, Thiel Foundation & Breakout Labs
- Rachel Rimsky, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson’s Research
- Daniel Smith, VP of Innovative Technologies, Autism Speaks
- Patricia Zilliox, Chief Drug Development Officer, Foundation Fighting Blindness
Panelists will address their specific investment criteria and unique missions; their particular investment decision-making process; the relevant questions to ask and the best approach to reach and heighten their interest; along with important trends to keep in mind.
If venture philanthropy investment is part of your plan to get your company funded, this panel is a fantastic opportunity to extend your network and expand your understanding of these organizations.
Next Phase Newsletter 
Leave a comment